Sec Form 13G Filing - SABBY MANAGEMENT LLC filing for PURPLE BIOTECH LTD. (PPBT) - 2021-01-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.1)*


Purple Biotech Ltd (fka Kitov Pharma Ltd.)
(Name of Issuer)


ADS
(Title of Class of Securities)


74638P109
(CUSIP Number)


December 31, 2020
(Date of Event Which Requires Filing of this Statement)


       Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
[_]  Rule 13d-1(b)

[X]  Rule 13d-1(c)

[_]  Rule 13d-1(d)

__________
       *The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing
information which would alter the disclosures provided in a prior cover
page.
       The information required in the remainder of this cover page shall
not be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934 (Act) or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
?
CUSIP No.
74638P109





1.
NAME OF REPORTING PERSONS








Sabby Volatility Warrant Master Fund, Ltd.




2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)


(a)  [_]


(b)  [X]



3.
SEC USE ONLY










4.
CITIZENSHIP OR PLACE OF ORGANIZATION





Cayman Islands




NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH



5.
SOLE VOTING POWER





0




6.
SHARED VOTING POWER





 739,662




7.
SOLE DISPOSITIVE POWER





0




8.
SHARED DISPOSITIVE POWER





 739,662




9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON




 739,662




10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (SEE INSTRUCTIONS)



[_]






11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)





4.30




12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

              CO?

CUSIP No.
74638P109





1.
NAME OF REPORTING PERSONS








Sabby Management, LLC




2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)


(a)  [_]


(b)  [X]



3.
SEC USE ONLY










4.
CITIZENSHIP OR PLACE OF ORGANIZATION





Delaware, USA




NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH



5.
SOLE VOTING POWER





0




6.
SHARED VOTING POWER





 739,662




7.
SOLE DISPOSITIVE POWER





0




8.
SHARED DISPOSITIVE POWER





 739,662




9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON




 739,662




10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (SEE INSTRUCTIONS)



[_]






11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)





4.30




12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

              OO
CUSIP No.
74638P109





1.
NAME OF REPORTING PERSONS








Hal Mintz




2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)


(a)  [_]


(b)  [X]



3.
SEC USE ONLY










4.
CITIZENSHIP OR PLACE OF ORGANIZATION





USA




NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH



5.
SOLE VOTING POWER





0




6.
SHARED VOTING POWER





 739,662




7.
SOLE DISPOSITIVE POWER





0




8.
SHARED DISPOSITIVE POWER





 739,662




9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON




 739,662




10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES (SEE INSTRUCTIONS)



[_]






11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)





4.30




12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

              IN?

CUSIP No.
74638P109



Item 1.
(a).
Name of Issuer:







Purple Biotech Ltd (fka Kitov Pharma Ltd.)



(b).
Address of issuer's principal executive offices:





One Azrieli Center, Round Tower
132 Menachem Begin Road
Tel Aviv 6701101, Israel


Item 2.
(a).
Name of person filing:







Sabby Volatility Warrant Master Fund, Ltd.
Sabby Management, LLC
Hal Mintz




(b).
Address or principal business office or, if none, residence:




Sabby Volatility Warrant Master Fund, Ltd.
c/o Ogier Fiduciary Services (Cayman) Limited
89 Nexus Way, Camana Bay
Grand Cayman KY1-9007
Cayman Islands

Sabby Management, LLC
10 Mountainview Road, Suite 205
Upper Saddle River, New Jersey 07458

Hal Mintz
c/o Sabby Management, LLC
10 Mountainview Road, Suite 205
Upper Saddle River, New Jersey 07458







(c).
Citizenship:




Sabby Volatility Warrant Master Fund, Ltd. - Cayman Islands
Sabby Management, LLC - Delaware, USA
Hal Mintz - USA







(d).
Title of class of securities:







ADS (the ADS)



(e).
CUSIP No.:







74638P109


Item 3.
If This Statement is filed pursuant to Section 240.13d-1(b) or
240.13d-2(b), or (c), check whether the person filing is a


(a)
[_]
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).


(b)
[_]
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


(c)
[_]
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C.
78c).


(d)
[_]
Investment company registered under section 8 of the Investment Company
Act of 1940 (15 U.S.C. 80a-8).


(e)
[_]
An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


(f)
[_]
An employee benefit plan or endowment fund in accordance with Section
240.13d-1(b)(1)(ii)(F);


(g)
[_]
A parent holding company or control person in accordance with Section
240.13d-1(b)(1)(ii)(G);



(h)
[_]
A savings association as defined in Section 3(b) of the Federal Deposit
Insurance Act (12 U.S.C.1813);


(i)
[_]
A church plan that is excluded from the definition of an investment
company under section 3(c)(14) of the Investment Company Act of 1940
(15 U.S.C. 80a-3);


(j)
[_]
A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


(k)
[_]
Group, in accordance with Section 240.13d-1(b)(1)(ii)(K).  If filing as
a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:







Item 4.
Ownership.


Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in
Item 1.


(a)
Amount beneficially owned:

Sabby Volatility Warrant Master Fund, Ltd. -  739,662

Sabby Management, LLC -  739,662

Hal Mintz - 739,662


(b)
Percent of class:

Sabby Volatility Warrant Master Fund, Ltd. - 4.30%

Sabby Management, LLC - 4.30%

Hal Mintz - 4.30%






(  (c)
Number of shares as to which the person has:



Sabby Volatility Warrant Master Fund, Ltd.



( (i)
Sole power to vote or to direct the vote
0
,







( (ii)
Shared power to vote or to direct the vote
 739,662
,







( (iii)
Sole power to dispose or to direct the disposition of
0
,







( (iv)
Shared power to dispose or to direct the disposition of
 739,662
..








Sabby Management, LLC



  (i)
Sole power to vote or to direct the vote
0
,







( (ii)
Shared power to vote or to direct the vote
 739,662
,







( (iii)
Sole power to dispose or to direct the disposition of
0
,







( (iv)
Shared power to dispose or to direct the disposition of
 739,662
..








Hal Mintz



( (i)
Sole power to vote or to direct the vote
0
,







( (ii)
Shared power to vote or to direct the vote
 739,662
,







( (iii)
Sole power to dispose or to direct the disposition of
0
,







( (iv)
Shared power to dispose or to direct the disposition of
 739,662
..








As calculated in accordance with Rule 13d-3 of the Securities Exchange
Act of 1934, as amended, (i) Sabby Volatility Warrant Master Fund,
Ltd. beneficially owns 739,662 shares of the Issuer's ADS,
representing approximately 4.30% of the ADS,
and (ii) Sabby Management, LLC and Hal Mintz each beneficially own
739,662 shares of the ADS, representing approximately 4.30% of
the ADS. Sabby Management, LLC and Hal Mintz do not directly own
any shares of ADS, but each indirectly owns 739,662 shares of
ADS. Sabby Management, LLC, a Delaware limited liability company,
indirectly owns 739,662 shares of ADS because it serves as the
investment manager of Sabby Volatility Warrant Master Fund, Ltd. Mr.
Mintz indirectly owns 739,662 shares of ADS in his capacity
as manager of Sabby Management, LLC.


Item 5.
Ownership of Five Percent or Less of a Class.


If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of
more than five percent of the class of securities, check the
following  [X].






?
Item 6.
Ownership of More Than Five Percent on Behalf of Another Person.





Not applicable



Item 7.
Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company or Control
Person.





Not applicable



Item 8.
Identification and Classification of Members of the Group.





Not applicable



Item 9.
Notice of Dissolution of Group.





Not applicable



?
Item 10.
Certification.




By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control
of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction having that
purpose or effect.



?
SIGNATURE

       After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is
true, complete and correct.

January 5, 2021

(Date)





Sabby Volatility Warrant Master Fund, Ltd.

By: /s/ Harry Thompson
	Name:  Harry Thompson
 Title:   Authorized Person of TDF Management Ltd.,
a Director



Sabby Management, LLC*

By: /s/ Robert Grundstein
	Name:  Robert Grundstein
       Title:   Chief Operating Officer






/s/ Hal Mintz*
 Hal Mintz

*This Reporting Person disclaims beneficial ownership over the securities
reported herein except to the extent of its pecuniary interest therein.

The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative.  If the statement
is signed on behalf of a person by his authorized representative other
than an executive officer or general partner of the filing person,
evidence of the representative's authority to sign on behalf of such
person shall be filed with the statement, provided, however, that a power
of attorney for this purpose which is already on file with the Commission
may be incorporated by reference.  The name and any title of each person
who signs the statement shall be typed or printed beneath his signature.

Note.  Schedules filed in paper format shall include a signed original
and five copies of the schedule, including all exhibits. See s.240.13d-7
for other parties for whom copies are to be sent.

Attention.  Intentional misstatements or omissions of fact constitute
Federal criminal violations (see 18 U.S.C. 1001).

EXHIBIT 1
----------

JOINT FILING AGREEMENT

       The undersigned hereby agree that this Statement on Schedule 13G
with respect to the beneficial ownership of shares of ADS of
Purple Biotech Ltd (fka Kitov Pharma Ltd.) is filed jointly, on behalf of
each of them.

Dated:  January 5, 2021

Sabby Volatility Warrant Master Fund, Ltd.

By: /s/ Harry Thompson
     Name:  Harry Thompson
     Title:   Authorized Person of TDF Management
Ltd.,    a Director
Sabby Management, LLC

By: /s/ Robert Grundstein
	Name:  Robert Grundstein
       Title:   Chief Operating Officer




/s/ Hal Mintz
 Hal Mintz